Impact of spironolactone exposure on prostate cancer incidence amongst men with heart failure: A Pharmacoepidemiological study

Time‐dependent multivariable analysis of spironolactone exposure following heart failure diagnosis in 18, 562 Canadian men found a reduced risk of prostate cancer (HR 0.55; 95% CI 0.31–0.98, P = 0.043).

British Journal of Clinical Pharmacology